{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:22:09Z","timestamp":1753888929067,"version":"3.41.2"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":344,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pharmacological and Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>This study demonstrated the impact of formic acid (FAc), a common reactive impurity in pharmaceutical excipients, on the stability of mirabegron (MB). The investigation of MB\u2010excipient compatibility tests revealed the formation of a new degradation product, FAc\u2010DP, at 0.2% after 7\u2009days of isothermal stress at 55\u00b0C. FAc\u2010DP was synthesized and characterized as N\u2010formyl MB using liquid chromatography\u2013mass spectrometry (LC\u2010MS) and both 1D and 2D nuclear magnetic resonance spectroscopy (NMR).<\/jats:p>","DOI":"10.1155\/adpp\/4971456","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T10:20:38Z","timestamp":1733826038000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification, Synthesis, and Characterization of N\u2010Formyl Mirabegron: A New Degradation Product Formed by Formic Acid Impurity in Pharmaceutical Excipients"],"prefix":"10.1155","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6864-7108","authenticated-orcid":false,"given":"Bashir","family":"Daoud Agha Dit Daoudy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ammar","family":"Al-Khayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2128-0251","authenticated-orcid":false,"given":"Ghassan","family":"Abo Chameh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Amer","family":"Al Mardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"e_1_2_10_1_2","unstructured":"FDA Approves Overactive Bladder Treatment MyrbetriqTM(Mirabegron) From Astellas https:\/\/www.astellas.com\/en\/."},{"key":"e_1_2_10_2_2","unstructured":"Astellas Garners New Indication & New Product Formulation Approvals From U.S. FDA for Children With Neurogenic Detrusor Overactivity (NDO) https:\/\/www.astellas.com\/en\/."},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02573-0"},{"key":"e_1_2_10_4_2","first-page":"66","article-title":"Drug-Excipient Interaction and Its Importance in Dosage Form Development","author":"Fathima N.","year":"2011","journal-title":"Journal of Applied Pharmaceutical Science"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.01.045"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c16-00929"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10337-022-04231-2"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2005.12.033"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4526396"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-011-9677-z"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2017.11.003"},{"key":"e_1_2_10_12_2","doi-asserted-by":"crossref","unstructured":"SharmaA. Effect of Residual Reactive Impurities in Excipients on the Stability of Pharmaceutical Products 2020.","DOI":"10.1002\/9783527812172.ch3"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-013-0015-5"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21119"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010037"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118910"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.11.014"},{"key":"e_1_2_10_18_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-12-802447-8.00006-6","volume-title":"Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice","author":"Narang A. S.","year":"2017"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2010.02.012"},{"volume-title":"Handbook of Pharmaceutical Excipients","year":"2009","author":"Rowe R. C.","key":"e_1_2_10_20_2"},{"key":"e_1_2_10_21_2","unstructured":"Center for Drug Evaluation and Research (CDER) Reviewer Guidance Validation of Chromatographic Methods 1994."},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9422(86)80102-9"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26164908"},{"key":"e_1_2_10_24_2","doi-asserted-by":"crossref","unstructured":"Quintanilla-LiceaR. Colunga-ValladaresJ. F. Caballero-QuinteroA.et al. Molecules NMR Detection of Isomers Arising From Restricted Rotation of the C-N Amide Bond of N-Formyl-O-Toluidine and N N\u2019-Bis-Formyl-o-Tolidine 2002.","DOI":"10.3390\/70800662"}],"container-title":["Advances in Pharmacological and Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/adpp\/4971456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T10:20:44Z","timestamp":1733826044000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/adpp\/4971456"}},"subtitle":[],"editor":[{"given":"Ezzouhra","family":"Elmaaiden","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1155\/adpp\/4971456"],"URL":"https:\/\/doi.org\/10.1155\/adpp\/4971456","archive":["Portico"],"relation":{},"ISSN":["2633-4682","2633-4690"],"issn-type":[{"type":"print","value":"2633-4682"},{"type":"electronic","value":"2633-4690"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2024-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"4971456"}}